TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06247605: Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line Treatment

Sponsor: Advenchen Laboratories Nanjing Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 243 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06247605 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06247605 Rescue Dossier →